AXS-05 meets primary endpoint for Alzheimer’s disease agitation study: industry news round-up
Musculoskeletal disorders are injuries or pain in the human musculoskeletal system, including the joints, ligaments, muscles, nerves, tendons, and structures that support limbs, neck and back.
This week in industry has seen various drugs meeting study endpoints and receiving US FDA approval. For example, AXS-05 meets its primary endpoint for Alzheimer’s disease (AD) agitation, ONGENTYS® receives US FDA approval as an add-on treatment for ‘OFF’ episodes in Parkinson’s disease (PD) and ocrelizumab may delay the risk of needing a walking aid in relapsing multiple sclerosis (MS). AXS-05 meets primary endpoint for Alzheimer’s disease agitation study ONGENTYS® receives US FDA approval as add-on treatment for ‘OFF’ episodes in Parkinson’s Ocrelizumab delays risk of needing walking aid in relapsing multiple sclerosis, new data reveals AXS-05 meets primary...
